Startseite>>Signaling Pathways>> Others>>PK14105

PK14105

Katalog-Nr.GC30398

PK14105 ist eine biologische Bewertung als potenzieller Radioligand fÜr PET-Untersuchungen von PBBS-Rezeptoren.

Products are for research use only. Not for human use. We do not sell to patients.

PK14105 Chemische Struktur

Cas No.: 107257-28-3

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
170,00 $
Auf Lager
2mg
129,00 $
Auf Lager
5mg
202,00 $
Auf Lager
10mg
295,00 $
Auf Lager
50mg
873,00 $
Auf Lager
100mg
1.379,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PK14105 is a biological evaluation as a potential radioligand for PET studies of PBBS receptors.in vivo binding experiments, in which PK 14105 was injected into rats with unilaterallylesioned striata, demonstrate that PK 14105 rapidly crosses the blood-brain-barrier and that thereis a marked retention of radioactivity in the lesioned striatum not seen in the unlesioned striatum or cerebellar vermis[1]It can also inhibit receptor ligands, calcium channel ligands and co-transporter in all salivary glands. [2]

[1]. Pascali C et al. The radiosynthesis of [18F]PK 14105 as an alternative radioligand for peripheral type benzodiazepine binding sites. Int J Rad Appl Instrum A. 1990;41(5):477-82. [2]. Franklin C. Wong et al. Affinity Labeling of Membrane Receptors Using Tissue-Penetrating Radiations. Biomed Res Int. 2013, 503095.

Bewertungen

Review for PK14105

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PK14105

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.